Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180885 | 1.00 | HTR6 (0.46) | HTR6CHRNB2CHRNA7CHRNA4HTR1D | |
| SCHEMBL6965704 | 0.86 | HTR6 (0.49) | HTR6CHRNB2CHRNA7CHRNA4HTR1D | |
| SCHEMBL6965707 | 0.86 | HTR6 (0.49) | HTR6CHRNB2CHRNA7CHRNA4HTR1D | |
| SCHEMBL6967984 | 0.86 | HTR6 (0.49) | HTR6CHRNB2CHRNA7CHRNA4HTR1D | |
| SCHEMBL8979664 | 0.86 | HTR6 (0.45) | HTR6CHRNB2CHRNA7CHRNA4HTR1D | |
| SCHEMBL19150272 | 0.86 | HTR6 (0.45) | HTR6CHRNB2CHRNA7CHRNA4HTR1D | |
| SCHEMBL14627126 | 0.84 | HTR6 (0.44) | HTR6HTR1DHTR1B | |
| SCHEMBL14593917 | 0.83 | HTR6 (0.43) | HTR6HTR1DHTR1B | |
| SCHEMBL7481650 | 0.78 | CNR2 (0.47) | HTR6HTR1DHTR1B | |
| SCHEMBL7481644 | 0.78 | CNR2 (0.47) | HTR6HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100430388-C | Improved process for the preparation of alpha-polymorphic eletriptan hydrobromide | PFIZER (US) | 2008-11-05 | — | — | CN | claimed |
| EP-1660485-B1 | IMPROVED PROCESS FOR PREPARING ALPHA-POLYMORPHIC ELETRIPTAN HYDROBROMIDE | PFIZER LTD (GB) | 2006-12-27 | — | — | EP | claimed |
| CN-1823060-A | Improved process for preparing alpha-polymorphic eletriptan hydrobromide | PFIZER (US) | 2006-08-23 | — | — | CN | claimed |
| US-20050245591-A1 | Process | PFIZER INC. | 2005-11-03 | — | — | US | claimed |
| US-20050020663-A1 | Process | FURLONG PATRICK JOSEPH (IE) | 2005-01-27 | — | — | US | claimed |
| WO-2012004811-A1 | PROCESS FOR THE PREPARATION OF 5-SUBSTSITUTED INDOLE DERIVATIVE | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011004391-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ELETRIPTAN AND ITS SALT THEREOF | MATRIX LABORATORIES LTD (IN) | 2011-01-13 | — | — | WO | disclosed |
| CN-100430388-C | Improved process for the preparation of alpha-polymorphic eletriptan hydrobromide | PFIZER (US) | 2008-11-05 | — | — | CN | disclosed |
| US-7288662-B2 | Process for the preparation of eletriptan | PFIZER, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7164030-B2 | Improved preparation of alpha -polymorphic eletriptan hydrobromide, by salt formation in a solution of 2-butanone and water, distillation, dehydration, desolventizing; purity, white color crystals | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| CN-1823060-A | Improved process for preparing alpha-polymorphic eletriptan hydrobromide | PFIZER (US) | 2006-08-23 | — | — | CN | disclosed |
| US-20050245591-A1 | Process | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1373254-B1 | Process for the preparation of the anti-migraine drug eletriptan | PFIZER LTD (GB) | 2005-11-02 | — | — | EP | disclosed |
| US-6927296-B2 | Process | PFIZER INC. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20050059828-A1 | Process for the preparation of eletriptan | PFIZER INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050020663-A1 | Process | FURLONG PATRICK JOSEPH (IE) | 2005-01-27 | — | — | US | disclosed |
| US-20030166704-A1 | New process | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245591-A1 | Process | TPSD1, TPSAB1, TPSB2 | HTR6 260/4885CHRNB2 52/4885CHRNA7 153/4885 |
| US-20050059828-A1 | Process for the preparation of eletriptan | TFPI, HTR3A, HTR3E | HTR6 20/4885CHRNB2 741/4885CHRNA7 433/4885 |
| US-20050020663-A1 | Process | TPSD1, TPSAB1, TPSB2 | HTR6 260/4885CHRNB2 52/4885CHRNA7 153/4885 |
| US-20030166704-A1 | New process | TFPI, HTR4, HTR5A | HTR6 20/4885CHRNB2 499/4885CHRNA7 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.